

Press release

Publication of 2018 Registration Document including the 2018 Financial Annual report

Toulouse, FRANCE, Lakeland, UNITED STATES, April 29, 2019, 7:00 pm CEST – CERENIS Therapeutics (FR0012616852 – CEREN – PEA-PME eligible), an international biopharmaceutical company dedicated to the discovery and development of innovative therapies for treating cardiovascular and metabolic diseases, as well as new HDL-based vectors for targeted drug delivery in the field of oncology and immuno-oncology, today announces the filing of its 2018 Registration Document under the number D.19-0432.

The document is available, free of charge, at the Company's headquarters (33-43 avenue Georges Pompidou – Bât D, 31130 Balma), and online on the website of the French Market Authorities (www.amf-france.org) and also on the Cerenis website (www.cerenis.com).

The following documents are integrated in the 2018 Registration Document:

- Report on corporate governance ;
- 2018 Financial Annual Report.

Financial calendar:

Cash position and revenue for Q2 2019: July 25, 2019

About CERENIS

Founded in 2005, Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative therapies. Cerenis' expertise has translated into a rich portfolio of programs for the treatment of cardiovascular disease and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy.



NewCap
Investor relations
Louis-Victor Delouvrier
cerenis@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Media relations
Nicolas Merigeau
cerenis@newcap.eu
+33 (0)1 44 71 94 98